

C1 On page 4, line 16, after "etc." insert -The hybridoma PM-1 was deposited as FERM BP-2998 on July 10, 1990, as an international deposit under the Budapest Treaty at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, 1-3, Higashi 1-chome, Tsukuba-shi Ibaraki-ken, 305, Japan.

IN THE CLAIMS:

Please cancel claims 16 - 23 without prejudice or disclaimer for filing in a continuing application. Kindly amend the claims as follows:

C2 --15. (Once amended) A method of treating a human subject having a disease caused by interleukin-6 (IL-6) production comprising administering to said human subject a therapeutically effective amount of an antibody to an IL-6 receptor in a pharmaceutically acceptable carrier, wherein the disease is cachexia and the therapeutically effective amount blocks signal transduction by IL-6 and inhibits the binding of IL-6 to the IL-6 receptor.

C3 25. (Once amended) The method according to claim 24, wherein said monoclonal antibody is the PM-1 antibody produced by [hyridoma] hybridoma PM-1, accession number FERM BP-2998.

C4 28. (Once amended) The method according to claim 27, wherein said humanized murine monoclonal antibody to an IL-6 receptor is a humanized PM-1 antibody, wherein the PM-1 antibody prior to humanization is produced by [hyridoma] hybridoma PM-1, accession number FERM BP-2998.

REMARKS

Claims 15-28 are presently pending in this application. Claims 16-22 are cancelled. Claims 15, 25 and 28 are amended. Support for the amendment to claim 15 is found in the paragraph bridging pages 3 - 4 of the specification and amendments to claims 25 and 28 are corrections of minor typographical errors. The specification is amended on page 1 to add